Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer

Prostate Cancer Clinical Trial

Official title:

Evaluation of Lymph Node Metastases in Men Undergoing Treatment With Sipuleucel-T for Metastatic Castrate-resistant Prostate Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02036918
• Other study ID #: Pro00047231
• Status: Completed
• Phase: Phase 1
• Start date: March 2014
• Est. completion date: February 6, 2019

Study information

• Verified date: March 2020
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aims to evaluate patients with metastatic castrate-resistant prostate cancer (mCRPC) undergoing treatment with sipuleucel-T for evidence of treatment-associated immune activation in lymph nodes and peripheral blood.

Description:

This is a pilot study of mCRPC patients planning to undergo therapy with sipuleucel-T immunotherapy. Consenting patients will be randomized 3:1 between immediate sipuleucel-T immunotherapy followed by lymph node biopsy (the post-treatment experimental group) or immediate lymph node biopsy followed by sipuleucel-T immunotherapy (the pre-treatment control group). Peripheral blood will be collected before, during, and after treatment with sipuleucel-T and evaluated for evidence of sipuleucel-T induced immune activation. Lymph nodes collected at biopsy will also be evaluated for evidence of sipuleucel-T induced immune activation. Patients will be followed for 3 months for safety and 6 months for disease progression.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 20
• Est. completion date: February 6, 2019
• Est. primary completion date: February 6, 2019
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age = 18 years

2. ECOG performance status 0 or 1

3. Life expectancy of = 6 months

4. Minimally-symptomatic or asymptomatic, castrate-resistant metastatic prostate cancer, as evidenced by all of the following:

1. Histologically-confirmed diagnosis of adenocarcinoma of the prostate

2. Evidence of adequate androgen deprivation, as evidence by one of the following:

• Bilateral orchiectomy

• Ongoing LHRH agonist (e.g. leuprolide, goserelin) and serum testosterone <50 ng/dl

• Ongoing LHRH antagonist (e.g. degarelix) and serum testosterone <50 ng/dl

3. Evidence of prostate cancer resistance to castration, as evidenced by one of the following:

• 2 consecutive PSA levels that are = 50% above the PSA nadir achieved on ADT and obtained at least 1 week apart

• CT or MRI based evidence of disease progression (soft tissue or nodal) according to PCWG2 criteria or RECIST 1.1 criteria, or at least 1 new bone scan lesion as compared to the most immediate prior radiologic studies.

4. Presence of non-visceral metastases on imaging

5. Absence of major symptoms directly attributable to prostate cancer, with the following permissible exceptions:

• Ureteral obstruction secondary to pelvic or retroperitoneal lymphadenopathy

• Bladder outlet obstruction secondary to locally recurrent prostate cancer

5. Radiographic evidence of lymphadenopathy, defined as a lymph node greater than 1 cm in diameter on axial imaging (CT or MRI or PET/CT)

6. Adequate laboratory parameters

7. A minimum of 4 weeks from any major surgery prior to registration. Coincident standard of care surgery with the research biopsy is permitted during the study.

Exclusion Criteria:

1. Prior treatment with sipuleucel-T

2. Allergy to any component of sipuleucel-T

3. Inability to undergo leukapheresis

4. History of neuroendocrine variants of prostate cancer, including small cell carcinoma of the prostate

5. Extensive prior surgery/radiation present that would render the biopsy highly complex and the risk of intraoperative injury high

6. Any chronic medical condition requiring daily corticosteroids or other immunosuppressants

7. Solid organ transplantation requiring immunosuppression

8. Visceral (e.g. lung, liver) metastases

9. Known brain metastases

10. History of spinal cord compression

11. Untreated/unstabilized pathologic long bone fractures

12. Other malignancy, except non-melanoma skin cancer, with a = 30% probability of recurrence within 24 months

13. Administration of any investigational therapeutic within 30 days of registration

14. Any condition which, in the opinion of the investigator, would preclude participation in this trial

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Drug:
• Sipuleucel-T

Procedure:
• Lymph Node Biopsy

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	anti-PA2024 immune response in lymph node-derived leukocytes	Proportion of patients with lymph node-derived leukocytes showing anti-PA2024 activity as measured by IFN? ELISPOT	Lymph node biopsy, approximately 10 weeks
Primary	anti-PAP immune response in lymph node-derived leukocytes	Proportion of patients with lymph node-derived leukocytes showing anti-PAP activity as measured by IFN? ELISPOT	Lymph node biopsy, approximately 10 weeks
Primary	anti-PA2024 immune response in PBMCs	Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFN? ELISPOT at each time point	Baseline
Primary	anti-PAP immune response in PBMCs	Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFN? ELISPOT at each time point	Baseline
Primary	anti-PA2024 immune response in PBMCs	Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFN? ELISPOT at each time point	Prior to sipuleucel-T infusion 2, approximately 6 weeks
Primary	anti-PAP immune response in PBMCs	Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFN? ELISPOT at each time point	Prior to sipuleucel-T infusion 2, approximately 6 weeks
Primary	anti-PA2024 immune response in PBMCs	Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFN? ELISPOT at each time point	Prior to sipuleucel-T infusion 3, approximately 8 weeks
Primary	anti-PAP immune response in PBMCs	Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFN? ELISPOT at each time point	Prior to sipuleucel-T infusion 3, approximately 8 weeks
Primary	anti-PA2024 immune response in PBMCs	Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFN? ELISPOT at each time point	2 weeks after the last sipuleucel-T infusion
Primary	anti-PAP immune response in PBMCs	Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFN? ELISPOT at each time point	2 weeks after the last sipuleucel-T infusion
Primary	anti-PA2024 immune response in PBMCs	Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFN? ELISPOT at each time point	3 months post-treatment
Primary	anti-PAP immune response in PBMCs	Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFN? ELISPOT at each time point	3 months post-treatment
Primary	anti-PA2024 immune response in PBMCs	Proportion of patients with PBMC samples showing anti-PA2024 activity as measured by IFN? ELISPOT at each time point	6 months post-treatment
Primary	anti-PAP immune response in PBMCs	Proportion of patients with PBMC samples showing anti-PAP activity as measured by IFN? ELISPOT at each time point	6 months post-treatment
Secondary	Serum anti-PA2024 antibody level	Describe any relationship between the magnitude of sipuleucel-T induced leukocyte activation observed in tumor-bearing lymph nodes with systemic (i.e. peripheral blood) studies of sipuleucel-T-induced immune activation	Baseline, up to 6 months post-treatment
Secondary	serum anti-PAP antibody level	Describe any relationship between the magnitude of sipuleucel-T induced leukocyte activation observed in tumor-bearing lymph nodes with systemic (i.e. peripheral blood) studies of sipuleucel-T-induced immune activation	Baseline, up to 6 months post-treatment